US FDA issues draft opioids guidance in hope of spurring abuse-deterrent technologies
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration on 9 January met its legislative deadline to issue a draft guidance document to help pharmaceutical firms develop new formulations of opioid drugs with abuse-deterrent properties1,2.